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ABSTRACT 
 
Background: Scientific understanding of obstructive sleep apnea (OSA) has increased exponentially 
during recent decades, suggesting a link between OSA and cardiovascular disease. Few randomized 
controlled trials exist within the field.  
 
Aim: To study the effect of continuous positive airway pressure (CPAP) on mechanisms contributing 
to cardiovascular disease deterioration.  
 
Methods and Results: Paper I is a cross-sectional analysis of revascularized patients with coronary 
artery disease (CAD). Patients with concomitant OSA had higher levels of inflammatory markers, 
independent of obesity. In paper II, the effect of losartan on blood pressure (BP) was investigated in 
patients with new-onset hypertension and OSA compared to patients with hypertension only. In 
addition, the effect on blood pressure of CPAP treatment in addition to losartan was investigated. 
Losartan reduced BP significantly in OSA but the reductions were less than in patients without OSA. 
Add-on CPAP treatment reduced night-time blood pressure in OSA patients in the intention-to-treat 
population, and all 24-h measurements in those compliant with CPAP. Paper III demonstrates that 
inflammatory markers decreases after one year in all CAD patients, and this was independent of 
CPAP in OSA. In paper IV, hypertensive patients with OSA responded with smaller reductions in 
aldosterone than patients without OSA after losartan. Add-on CPAP treatment tended to lower 
aldosterone, but the reductions were more robust in the sympathetic activity. No effect was seen on 
the inflammatory markers.  
 
Conclusions: Inflammatory markers are high in newly revascularized CAD patients with OSA, but 
the levels decrease over time independent of CPAP treatment, suggesting that the initial increase in 
inflammatory activity in CAD with concomitant OSA is most probably driven by other factors. 
Blood pressure in new-onset hypertension seems to be reduced by CPAP as add-on treatment to 
losartan; this may be attributed mainly to sympathetic activity and, to a lesser extent, to RAAS 
activity, whereas inflammation seems to be of minor importance.                                        
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